Aplastic Anemia Treatment: IST and Stem Cell Transplants

Aplastic anemia treatment today centers on two main strategies: hematopoietic stem cell transplantation, which can cure the disease, and immunosuppressive therapy, which quiets the immune attack on the bone marrow and allows blood counts to recover. The choice between them depends heavily on the patient’s age and whether a suitable donor is available. What was once a nearly universally fatal diagnosis can now be treated successfully in the majority of cases, and the options keep improving as newer drugs enter clinical practice.

Why the Immune System Is the Target

Acquired aplastic anemia is an autoimmune disease. The body’s own T cells attack the stem cells in the bone marrow that produce red blood cells, white blood cells, and platelets.¹ This leaves the marrow nearly empty, which is why blood counts drop across the board. In most patients, there is no identifiable trigger. The condition can appear at any age, though it peaks in young adults and again in people over 60.

Because the root problem is immune-driven destruction rather than a defect in the stem cells themselves, suppressing the rogue immune response can let the marrow recover. That insight, developed over several decades, transformed aplastic anemia from a disease with a grim prognosis into one where most patients can expect long-term survival.²

How Treatment Decisions Are Made

The single biggest fork in the road is whether a young patient has a matched sibling donor. If a patient under roughly 40 has a fully matched brother or sister willing to donate, a bone marrow transplant is the preferred first-line treatment. Transplant from a matched sibling is considered the standard of care for young patients with severe disease because it offers the best chance of a durable cure.³ Current guidelines from the American Society of Hematology reinforce this, recommending transplantation first for younger patients with an available matched sibling or unrelated donor, and positioning it as a second-line option after immunosuppressive therapy fails in other patients.⁴

For older patients, those without a matched sibling, or those who are too ill for an immediate transplant, immunosuppressive therapy is the first step. The age cutoffs are not rigid, but in practice, transplant-related complications rise with age, so doctors weigh the risks differently for someone who is 25 versus someone who is 55.

Immunosuppressive Therapy With ATG and Cyclosporine

The backbone of immunosuppressive treatment is a combination of anti-thymocyte globulin (ATG) and cyclosporine. ATG is an antibody preparation derived from horses or rabbits that depletes the overactive T cells destroying the bone marrow. Cyclosporine is an oral drug that keeps the remaining T cells suppressed over a longer period. Together, they give the marrow breathing room to regenerate.

Response rates with horse ATG plus cyclosporine hover around 60 to 70 percent at six months. In a large NIH cohort of 104 consecutive patients with severe disease, the overall response rate at six months was 62 percent.⁵ Those who respond robustly tend to do well long term. The catch is that response is not instantaneous: blood counts can take weeks to months to improve, and some patients need repeated courses.

An important clinical question has been whether horse or rabbit ATG works better. A head-to-head trial showed a striking difference in favor of horse ATG, with a 68 percent response rate compared to 37 percent for rabbit ATG at six months.⁶ A meta-analysis confirmed that horse ATG was associated with a significantly higher overall response rate.⁷ In children, the picture was somewhat more balanced; a large retrospective study found response rates of 61 percent and 55 percent at six months for horse and rabbit ATG, respectively, a gap that was not statistically significant.⁸ Still, horse ATG is the standard first-line choice in most treatment centers worldwide.

Adding Eltrombopag to Immunosuppression

One of the most significant recent advances in aplastic anemia treatment is the addition of eltrombopag, a drug that stimulates the bone marrow to produce more blood cells by mimicking the hormone thrombopoietin. Rather than just suppressing the immune attack, eltrombopag directly nudges the remaining stem cells to grow. When added to standard ATG and cyclosporine for previously untreated severe aplastic anemia, it improved the rate, speed, and strength of blood count recovery without additional toxic effects. Patients receiving eltrombopag alongside immunosuppression had their first response at a median of three months, compared to nearly nine months with immunosuppression alone.⁹

Longer follow-up from the European RACE trial has been encouraging. The initial response advantage translated into better two-year overall survival and disease-free survival, and the addition of eltrombopag did not increase the risk of the bone marrow evolving into a secondary blood cancer.¹⁰ These results have made eltrombopag plus ATG and cyclosporine the emerging standard of care for first-line treatment when transplant is not an option.

Stem Cell Transplantation

For patients who receive a transplant, the donor’s healthy stem cells replace the damaged bone marrow. A matched sibling transplant remains the gold standard, but only about 25 to 30 percent of patients have a fully matched sibling. When a sibling is unavailable, a matched unrelated donor can be used. Conditioning regimens combining fludarabine, cyclophosphamide, and ATG, sometimes with a low dose of total-body irradiation, have yielded five-year survival rates in the range of 73 to 79 percent for unrelated donor transplants.¹¹

A newer frontier is haploidentical, or “half-matched,” transplantation. Almost every patient has a parent, child, or sibling who shares half of their tissue-matching markers, making the donor pool much larger. The main challenge with half-matched donors has historically been graft-versus-host disease, where the donated immune cells attack the recipient’s tissues. The use of high-dose cyclophosphamide given shortly after transplant has dramatically reduced this complication.¹²

Early European data on haploidentical transplants with post-transplant cyclophosphamide showed two-year overall survival of 78 percent and low rates of both acute and chronic graft-versus-host disease.¹³ A separate multicenter series of 16 patients reported a 94 percent rate of neutrophil engraftment and low rates of graft-versus-host disease, though one-year survival was 67 percent in that smaller cohort.¹⁴ These early results are promising enough that haploidentical transplant is increasingly offered to patients who lack a matched donor and have failed immunosuppressive therapy.

The choice of conditioning regimen matters. A study using fludarabine and cyclophosphamide with ATG in matched-sibling transplants for severe aplastic anemia reported two-year overall and event-free survival of 100 percent, with no graft failures.¹⁵ Results like these underscore how refinements in transplant technique continue to push outcomes upward.

Supportive Care Throughout Treatment

Regardless of whether someone is heading toward a transplant or immunosuppressive therapy, supportive care is a constant companion. Blood and platelet transfusions keep patients safe while their marrow is not producing enough cells on its own. Antimicrobial prophylaxis and rapid treatment of infections are also central to management, since low white blood cell counts leave patients vulnerable to bacterial, viral, and fungal infections.¹⁶ Prophylactic medications can include antibiotics, antivirals, and antifungals, tailored to the patient’s level of immune suppression.¹⁷

Repeated red blood cell transfusions create a secondary problem: iron overload. The body has no efficient way to excrete excess iron, so it accumulates in organs like the liver and kidneys. In aplastic anemia patients, elevated iron stores have been linked to liver and kidney dysfunction.¹⁸ Iron chelation therapy, most commonly with the oral drug deferasirox, brings iron levels back down. In a large prospective study of 116 aplastic anemia patients, one year of deferasirox reduced median serum ferritin from over 3,200 to about 1,850 ng/mL.¹⁹ A smaller case series even found that some patients became transfusion-independent after chelation, suggesting that reducing iron burden may itself benefit blood production.²⁰

Side Effects of Cyclosporine

Cyclosporine is usually continued for months to years after the initial ATG course, and long-term use comes with a well-known profile of side effects. In a large study tracking adverse events, the most common problems included excess hair growth (about 72 percent of patients), gum overgrowth (around 61 percent), elevated uric acid (about 63 percent), abnormal cholesterol (47 percent), and rising creatinine levels suggesting kidney stress (40 percent).²¹ Most of these effects are manageable, but the kidney risk deserves attention. Patients who needed prolonged cyclosporine courses had a chronic kidney disease rate of about 27 percent, compared to roughly 8 percent in those who received a shorter course.²² This is one reason doctors try to taper cyclosporine once blood counts are stable, rather than keeping patients on it indefinitely.

The Risk of Clonal Evolution

Even after successful treatment, the damaged bone marrow remains at risk of developing genetic changes that push it toward myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Roughly 15 to 20 percent of aplastic anemia patients develop secondary MDS or AML within ten years.²³ This is not a side effect of any particular treatment; it reflects the biology of a bone marrow that has been under siege. Stem cells that survive the immune attack may harbor mutations, and as they work overtime to replenish blood counts, those mutations can expand.²⁴

This risk means that patients who respond to immunosuppressive therapy still need long-term monitoring with periodic blood tests and sometimes bone marrow biopsies. Identifying clonal evolution early can guide decisions about whether a transplant is warranted even after a successful response to immunosuppression.

When First-Line Treatment Fails

About a third of patients do not respond to the initial round of horse ATG and cyclosporine. Among those who do respond, relapse is common: in the NIH cohort, 37 percent of responders relapsed at a median of about 13 months.²⁵ Options for refractory or relapsed disease include a second course of ATG (sometimes switching from horse to rabbit), alemtuzumab, or eltrombopag.²⁶ For patients who fail immunosuppression entirely, transplantation from an unrelated or haploidentical donor becomes the next step.

Telomere Length as a Diagnostic and Prognostic Tool

Telomeres, the protective caps on chromosome ends, turn out to be relevant in aplastic anemia in ways that go beyond academic interest. About a third of patients with acquired aplastic anemia have abnormally short telomeres, and some carry mutations in the genes that maintain telomere length.²⁷ This matters clinically for two reasons.

First, telomere length measurement helps distinguish acquired aplastic anemia from inherited bone marrow failure syndromes like dyskeratosis congenita, which can look similar on routine testing. In one study of 105 unclassified bone marrow failure patients, a telomere length below the first percentile for age identified inherited syndromes with over 90 percent sensitivity and about 88 percent specificity.²⁸ Getting this distinction right matters because inherited conditions often require different treatment approaches and carry different risks.

Second, even among patients with clearly acquired disease, shorter telomeres predict a worse response to immunosuppressive therapy.²⁹ Patients with very short telomeres may be steered toward transplant earlier rather than spending months on immunosuppression that is less likely to work.

Newer Thrombopoietin Receptor Agonists

While eltrombopag has become established in first-line therapy, other drugs in the same class are showing promise for patients who relapse or do not tolerate eltrombopag well. Romiplostim, which is given by injection rather than taken orally, showed encouraging results in a small study of patients who had failed multiple prior thrombopoietin receptor agonists. About 73 percent responded, with more than half achieving a complete response at a median of about two and a half months, and no serious drug-related side effects led to stopping treatment.³⁰

Avatrombopag, another oral option, has been studied in a phase 2 trial of patients with non-severe aplastic anemia who had relapsed or could not tolerate other treatments. The overall response rate at three months was 56 percent, and even patients who had previously failed eltrombopag showed responses, suggesting the two drugs are not perfectly interchangeable in how they interact with the bone marrow.³¹ Having multiple drugs in this class gives doctors more flexibility, especially for patients cycling through treatments.

Quality of Life After Treatment

Survival statistics can obscure what daily life is actually like for someone living with aplastic anemia. Even after successful immunosuppressive therapy, the disease continues to affect patients physically and psychologically. In one study, 83 percent of patients who had responded to immunosuppression still reported fatigue.³² Interestingly, patients with a partial response sometimes reported higher quality-of-life scores than those with a complete response, particularly in domains related to psychological well-being and fear of disease progression. The reason is not entirely clear, but patients who still feel monitored closely may paradoxically feel more secure.

For patients dependent on regular transfusions, the toll on daily routine is substantial. Some patients need at least one blood component transfusion every couple of months, a pattern that can stretch on for years.³³ The time spent traveling to infusion centers, the physical effects of fluctuating blood counts between transfusions, and the psychological weight of depending on donated blood all add up. Addressing quality of life is increasingly recognized as part of treatment planning, not just an afterthought.

Gene Therapy on the Horizon

For the subset of aplastic anemia cases linked to short telomeres, a fundamentally different approach is under investigation: delivering the gene for telomerase directly into bone marrow cells. In mouse models of aplastic anemia caused by telomere shortening, a single treatment with an adeno-associated virus vector carrying the telomerase gene rescued bone marrow function, lengthened telomeres in both blood and marrow cells, and improved survival compared to untreated controls.³⁴ This is still years away from human application, and it would only help patients whose disease is driven by telomere defects. But it represents a conceptually elegant strategy: rather than suppressing the immune system or replacing the marrow entirely, you fix the underlying vulnerability that made the stem cells fragile in the first place.